Highlights Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-24 pm EDT			5-day change	1st Jan Change
985 ^USD	+0.45%		+0.28%	+12.15%

May. 23	Regeneron Pharmaceuticals Says GN7075 Plus Libtayo Shows Anti-Tumor Responses in Microsatellite Stable Colorectal Cancer	MT
May. 23	Regeneron Pharmaceuticals, Inc. Announces Positive New Results from an Ongoing Phase 1/2 Trial Evaluating its First-in-Class Costimulatory Bispecific Antibody, REGN7075	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Regeneron Pharmaceuticals Says GN7075 Plus Libtayo Shows Anti-Tumor Responses in Microsatellite Stable Colorectal Cancer	May. 23	MT
Regeneron Pharmaceuticals, Inc. Announces Positive New Results from an Ongoing Phase 1/2 Trial Evaluating its First-in-Class Costimulatory Bispecific Antibody, REGN7075	May. 23	CI
Regeneron, Sanofi Disclose Positive Results for Lung Disease Treatment Candidate	May. 20	MT
Piper Sandler Adjusts Price Target on Regeneron Pharmaceuticals to $1,000 From $1,000.25	May. 20	MT
Sector Update: Health Care Stocks Mixed Late Afternoon	May. 17	MT
Regeneron, Sanofi Get Speedy FDA Review of Dupixent in Younger CRSwNP Group	May. 13	DJ
Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts for Priority Review the Supplemental Biologics License Application for Dupixent	May. 13	CI
Regeneron Pharmaceuticals, Inc. Announces Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness Within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks	May. 08	CI
Global markets live: Etsy, Qualcomm, Carvana, Rio Tinto, Apple...	May. 02
Sector Update: Health Care Stocks Mixed Premarket Thursday	May. 02	MT
Regeneron: Adjusted EPS down 4% in Q1	May. 02	CF
Tranche Update on Regeneron Pharmaceuticals, Inc.'s Equity Buyback Plan announced on February 3, 2023.	May. 02	CI
Regeneron Pharmaceuticals 1Q Revenue Declines Amid Lower EYLEA Sales	May. 02	DJ
Regeneron Pharmaceuticals' Q1 Non-GAAP Net Income, Revenue Decline	May. 02	MT
Regeneron Pharmaceuticals, Inc. announces an Equity Buyback for $3,000 million worth of its shares.	May. 02	CI
Stock Futures Gain Pre-Bell as Fed Leaves Key Rate Unchanged; Asia, Europe Churn	May. 02	MT
Earnings Flash (REGN) REGENERON PHARMACEUTICALS Reports Q1 Revenue $3.15B, vs. Street Est of $3.22B	May. 02	MT
Earnings Flash (REGN) REGENERON PHARMACEUTICALS Reports Q1 EPS $9.55, vs. Street Est of $10.10	May. 02	MT
Regeneron misses profit estimates on weaker Eylea and Dupixent sales	May. 02	RE
Regeneron Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Highlights

Filters